TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of AXS-05 in Patients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Age 18 - 65~* Currently meets DSM-5 criteria for MDD~* Body Mass Index between 18 and 40 kg/m\^2, inclusive~Key Exclusion Criteria:~* Suicide risk~* History of treatment resistance in current depressive episode~* History of electroconvulsive therapy, vagus nerve stimulation, transcranial magnetic stimulation or any experimental central nervous system treatment during the current episode or in the past 6 months~* Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AXS-05 (Type: EXPERIMENTAL): AXS-05 (bupropion and dextromethorphan) oral tablets
- Placebo (Type: PLACEBO_COMPARATOR): Placebo oral tablets to match AXS-05

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Pregnant women are eligible for inclusion into the Very High Risk Group if they:~* are PLA-1 (platelet antigen A1) negative and have known platelet incompatibility with their fetus~* have had a previous child who suffered an antenatal hemorrhage prior to 28 weeks gestation (as best as could be estimated)~* are less than 19 weeks gestation~Pregnant women are eligible for inclusion into the High Risk Group if they:~* are PLA-1 negative and have known platelet incompatibility with the fetus~* have had a previous child who suffered an antenatal hemorrhage after 28 weeks gestation (as best as could be estimated)~* are between 12-30 weeks gestation~Pregnant women are eligible for inclusion into the Standard Risk Group if they:~* are PLA-1 negative and have known platelet incompatibility with the fetus~* have not had a previous child who suffered an antenatal hemorrhage~* are between 20-30 weeks gestation~Exclusion Criteria:~Women are not eligible for inclusion into the Very High Risk Group if they:~* have had a previous child who suffered an antenatal hemorrhage after 28 weeks gestation~* are greater than 19 weeks gestation~Women are not eligible for inclusion into the High Risk Group if they:~* have had a previous child who suffered an antenatal hemorrhage prior to 28 weeks gestation~* are greater than 30 weeks gestation~Women are not eligible for inclusion into the Standard Risk Group if they:~* have had a previous child who suffered an antenatal hemorrhage~* are greater than 30 weeks gestation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- IVIG x 2 (Type: EXPERIMENTAL): IVIG 2 g/kg/wk divided into 2 infusions per week for women with a fetus affected by FNAIT
- IVIG x 1 + prednisone (Type: EXPERIMENTAL): IVIG 1 g/kg/wk in 1 infusion per week + prednisone 0.5 mg po daily for women with a fetus affected by FNAIT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have type 2 diabetes~* Have inadequate overall glycemic control (hemoglobin A1c greater than or equal to 7.0% and less than or equal to 12.0%) at or within 4 weeks prior to Visit 1~* Have used:~  * single or multiple OAMs for at least 3 months immediately prior to entering the study, including metformin, sulfonylurea, meglitinides (repaglinide, nateglinide), or alpha glucosidase inhibitors (acarbose, miglitol); or~ * insulin (once or twice daily) for at least 3 months immediately prior to entering the study; or~ * a combination of the above.~* Are greater than or equal to 21 and less than 80 years of age~* As determined by the investigator, are capable and willing to:~  * comply with their prescribed diet and medication regimen,~ * perform self blood glucose monitoring,~ * use the patient diary as required for this protocol,~ * participate in two 24 hour inpatient assessments~Exclusion Criteria:~* Have used a thiazolidinedione (pioglitazone or rosiglitazone) during the 3 months prior to entry into the study~* Are currently treated with a meglitinide without sulfonylurea~* Have a known allergy or intolerance to insulin lispro mix 75/25, insulin glargine, or metformin~* Have plasma creatinine greater than or equal to 1.5 mg/dL (for males) or greater than or equal to 1.4 mg/dL (for females) for patients who will be treated with metformin or; greater than 2 mg/dL for patients treated with other OAMs, as determined by a local laboratory~* Have received chronic (lasting longer than 2 weeks), systemic glucocorticoid therapy (excluding topical and inhaled preparations) within 4 weeks immediately prior to Visit 1

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Lispro mixture 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
- 2 (Type: ACTIVE_COMPARATOR): Glargine, once-daily, SC injection, given in conjunction with oral antidiabetic medications.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Combination Therapy to Treat COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent, demonstrating that the subject understands the procedures required for the study and the purpose of the study~2. Healthy male or female subjects at least 18 years of age~3. Diabetic and obese (BMI \> 30) patients will be included in the Trial but randomization will be stratified.~4. Positive test for COVID-19 by RT-PCR or rapid antigen test at screening~5. Subjects must agree to practice at least two highly effective methods of birth control for the duration of the study. One of these must be a barrier method. Exceptions for females and partners of females that are not of childbearing potential. (e.g. surgically sterilized, post-menopausal)~6. Subjects must agree they will attend the treatment facility daily for 10d in the event of failure to attend, the patient will be visited at their home to collect the nasal swab and review data.~Exclusion Criteria:~1. Refusal to sign informed consent form~2. Negative test for COVID-19 by RT-PCR at screening~3. Severe disease symptomatically including pneumonia, respiratory distress, tachypnea, shortness of breath, temperature \> 104.0 degrees F, pleuritic pain, or frequent cough.~4. Known drug allergy to any of the investigational medications~5. Currently taking medication with known drug interactions with investigational medications, found in Appendix II~6. Prescription or other antiviral medications~7. Any comorbidities which constitute health risk for the subject including known cardiac arrhythmias - but will be limited to those on hydroxychloroquine~8. Inability to attend daily for 10 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Arm (Type: EXPERIMENTAL): Patients will be treated with a combination of Ivermectin, Doxycycline, Zinc, Vitamin D3 and Vitamin C
- Placebo (Type: PLACEBO_COMPARATOR): Placebo and Vitamin D3, Vitamin C, and Zinc

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histologically confirmed nasopharyngeal carcinoma (AJCC 8th stage II-IVa) or cervical cancer (adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma, clinical FIGO stage Ib2-IVa;), planning to receive concurrent chemoradiotherapy),18 years or older, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.~Exclusion Criteria:~* took medications with antiemetic effect within 24 hours before initiation of concurrent chemoradiotherapy, had severe systemic diseases (such as uncontrolled diabetes/hypertension) or clinically unstable epileptic seizures require the use of anticonvulsants; allergic to fosaprepitant, tropisetron or dexamethasone.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- fosaprepitant group (Type: EXPERIMENTAL): Intravenous fosaprepitant of 150mg was given before cisplatin administration on day 1. All patients received tropisetron 5mg and dexamethasone 5mg infusion on day 1 and oral dexamethasone 3.75 mg once a day on day 2-3.
- control group (Type: ACTIVE_COMPARATOR): The control group was delivered tropisetron 5mg and dexamethasone 5mg only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients age 18 years or more.~* Histologically confirmed diagnosis of non-small-cell lung carcinoma.(and indifferentiated and BAC histology).~  * Only patients with advanced disease, defined as stage IV or IIIB with/without pleural effusion, will be included.~ * Tumor sample available.~ * A measurable lesion, as defined by RECIST criteria.~ * Karnofsky score 60% or more (ECOG \< 2).~ * Patients should not have received previous treatment with chemotherapy or other agents for disseminated disease. Chemotherapy is allowed if the initial diagnosis of the patient is limited disease and the patient has received adjuvant or neoadjuvant treatment.~* Patients with cerebral disease are permitted, without any time limitations after holocranial irradiation or complementary antiedema treatment.~* Patients with hepatical, renal and hematology normality values.~* Patients should sign an informed consent form before inclusion in the study that specifies that the clinical trial treatment entails consent for the analysis of biological samples of tumor and blood.~* Patients of childbearing age of either sex must use effective contraceptive methods (barrier methods or other birth control methods) before entering the study and while participating in the study.~* Patients must be available for clinical follow-up..~Exclusion Criteria:~* Patients who have received an investigational medicinal product in the 21 days before inclusion in the study or antiEGFR receptor agent.~* Severe comorbidity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 (Type: EXPERIMENTAL): The rest of the patients who do not carry the Factor Receptor mutation of Epidermal Growth will receive chemotherapy treatment individualized based on BRCA 1 m RNA levels. Function of these levels, three different subgroups of treatment: Subgroup A with low BRCA1 mRNA levels will receive treatment with gemcitabine / cisplatin Subgroup B with intermediate levels of BRCA1 mRNA: will receive treatment with docetaxel / cisplatin Subgroup C with high levels of BRCA1 mRNA: will receive treatment with docetaxel
- 1 (Type: EXPERIMENTAL): The group of patients carrying EGFR mutation will receive treatment with Erlotinib, a selective oral Receptor tyrosine kinase inhibitor Epidermal Growth Factor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria Patients with acute coronary syndromes with at least one additional risk factor for cardiovascular complications.~Exclusion criteria~1. Long term treatment with any other oral anticoagulant~2. Severe/disabling stroke within last 6 months~3. Conditions associated with increased bleeding risk~4. Anaemia or thrombocytopenia~5. Severe renal impairment~6. Liver disease~7. Positive pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabigatran etexilate 50mg (Type: EXPERIMENTAL): twice daily dosing,
- Dabigatran etexilate 75mg (Type: EXPERIMENTAL): twice daily dosing, patients with moderate renal impairment allocated 50mg bid
- Dabigatran etexilate 110mg (Type: EXPERIMENTAL): twice daily dosing, patients with moderate renal impairment allocated 75mg bid
- dabigatran etexilate 150mg (Type: EXPERIMENTAL): twice daily dosing, patients with moderate renal impairment allocated 110mg bid
- placebo (Type: PLACEBO_COMPARATOR): matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Circumferential Pulmonary Vein Ablation (CPVA) Versus Antiarrhythmic Drug Therapy in for Paroxysmal Atrial Fibrillation (AF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-70 years~2. History of symptomatic paroxysmal AF lasting more than 6 months. Paroxysms of AF are intended as recurrent self-terminating episodes lasting less than 7 days and occurring more than 2 times every month.~Exclusion Criteria:~1. Pregnancy~2. NYHA functional class III or IV~3. Left atrial size \> 65 mm~4. Left ventricular (LV) ejection fraction \< 35%~5. Contraindication to anticoagulation with warfarin~6. History of myocardial infarction within six months of the procedure~7. Prior catheter or surgical ablation attempt for AF~8. Inability or unwillingness to provide written informed consent~9. Life expectancy less than 1 year~10. Significant comorbid conditions such as: cancer (not cured), end stage renal disease (creatinine clearance \< 20 mL/h), severe chronic obstructive lung disease, cirrhosis, etc)~11. Anticipated cardiac surgery for congenital, valvular, aortic or coronary heart disease.~12. Presence of left atrial thrombus.~13. Prior antiarrhythmic drug therapy with amiodarone, sotalol and flecainide at optimal doses (target 200 mg, 240 mg, 200 mg daily respectively~14. AF burden \< 2 episodes/month~15. WPW~16. Expected survival \< 1 year~17. Contraindications for antiarrhythmics therapy including flecainide, sotalol or amiodarone not listed above:~    * LV hypertrophy (LV mass index \> 125g/m2)~   * thyroid dysfunction (hyperthyroidism or uncontrolled hypothyroidism or thyroid cancer)~   * liver dysfunction (ALT or AST \>2x the reference values)~   * Interstitial lung disease with DLCO\<70% of predicted or severe asthma.~   * QT interval exceeding 400 msec~   * Symptomatic sinus node or atrioventricular node dysfunction unless a pacemaker had been implanted~   * Evidence of stress-induced myocardial ischemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~General Inclusion Criteria:~1. Willing and able to provide informed consent;~2. 18 years of age and less than 75 years of age;~3. PE symptom duration ≤ 14 days;~4. Filling defect in at least one main or lobar pulmonary artery as determined by contrast enhanced chest CT;~5. RV/LV end diastolic diameter ratio ≥ 0.9 by CTA as determined by the investigative site;~6. Willing and able to comply with all study procedures and follow-up.~Exclusion Criteria:~1. Cerebrovascular Accident (CVA) or transient ischemic attack (TIA) within one (1) year;~2. Head trauma, or other active intracranial, or intraspinal disease within one (1) year;~3. Recent (within one month) or active bleeding from a major organ;~4. Intracranial condition(s) that may increase the risk of bleeding (e.g., neoplasms, arteriovenous malformations, or aneurysms);~5. Patients with bleeding diathesis;~6. Hematocrit \< 30%;~7. Platelets \< 100,000/μL;~8. INR \> 1.5;~9. aPTT \> 50 seconds in the absence of anticoagulants;~10. Major surgery within fourteen (14) days;~11. Serum creatinine \> 2 mg/dL;~12. Clinician deems high-risk for catastrophic bleeding;~13. History of heparin-induced thrombocytopenia (HIT);~14. Pregnancy;~15. Systolic blood pressure \< 90 mmHg for \> 15 minutes;~16. Any vasopressor support;~17. Cardiac arrest (including pulseless electrical activity and asystole) requiring active cardiopulmonary resuscitation (CPR);~18. Evidence of irreversible neurological compromise;~19. Life expectancy \< one (1) year;~20. Use of thrombolytics or glycoprotein IIb/IIIa antagonists within 3 days prior to inclusion in the study;~21. Use of non-vitamin K oral anti-coagulants (NOACs), such as Rivaroxaban, Apixaban, Dabigatran, Edoxaban within 48 hours prior to inclusion in the study;~22. Use of enoxaparin sodium injection (Lovenox®) within 12 hours of procedure start time;~23. Profound bradycardia requiring a temporary pacemaker and/or inotropic support;~24. Previous enrollment in this study;~25. Morbidly obese (BMI \>45 kg/m2) patient who by the judgement of the investigator is high risk for bleeding;~26. Absolute contraindication to anticoagulation;~27. Uncontrolled hypertension;~28. Currently participating in another study;~29. In the opinion of the investigator, the subject is not a suitable candidate for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BEC Treatment (Type: EXPERIMENTAL): The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically established coronary artery disease or carotid artery disease with greater than 15% stenosis by ultrasound~* Family history of cardiovascular disease~* Apolipoprotein B level greater than or equal to 120 mg/dL (LDL level should be between 100 and 190 mg/dL without medication)~* Has been undergoing lipid therapy for no more than 12 months before study entry~* Medically stable~* Medically able to undergo MRI procedure~Exclusion Criteria:~* Uses pacemaker or has metallic implants~* Has immediate plans for carotid endarterectomy~* History of alcohol or drug abuse~* Active liver disease or liver dysfunction, defined by elevations in alanine aminotransferase (ALT)/aspartate aminotransferase (AST) levels greater than 1.5 times the upper limit of normal~* Serum creatine kinase (CK) level greater than 3 times the upper limit of normal before study entry~* Serum creatinine level greater than 2.5 times the upper limit of normal~* Diabetes, with a fasting glucose level greater than 150 mg/dL or hemoglobin A1c (HbA1c) level greater than 8% before study entry~* Uncontrolled high blood pressure, defined as average resting systolic blood pressure greater than 200 mm Hg or average resting diastolic blood pressure greater than 95 mm Hg

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 - single therapy group (Type: ACTIVE_COMPARATOR): Participants will receive atorvastatin, placebo niacin, and placebo colesevelam. The treatment target for LDL-C will be ≤80 mg/dl for the single therapy group.
- 2 - double therapy group (Type: EXPERIMENTAL): Participants will receive atorvastatin, niacin, and placebo colesevelam. The treatment target for LDL-C will be ≤80 mg/dl for the double therapy group.
- 3 - triple therapy group (Type: EXPERIMENTAL): Participants will receive atorvastatin, niacin, and colesevelam. The treatment target for LDL-C will be ≤60 mg/dl for the triple therapy group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete